Friedman Billings Downgrades Progenics Pharma (PGNX) to Underperform
More News related to PGNX
- Progenics (PGNX) Said RELISTOR Clinical Trials Initiated in Japan
- Progenics Pharmaceuticals (PGNX) Ends Hepatitis C Program PRO 206
- Progenics Provides Update on Hepatitis C Program
- Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
- Progenics Announces First Quarter Financial Results
Friedman Billings downgrades Progenics Pharmaceuticals (Nasdaq: PGNX) from Market Perform to Underperform with a $12 price target.
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat debilitating conditions and life-threatening diseases in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
-0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
